Abstract
Functionally inter-connected large-scale brain networks regulated by multiple neurotransmitter systems underpin complex human behaviour. A wide range of alterations in this neurofunctional landscape have been associated with autism. However, this evidence is mostly derived from cross-sectional analyses and thus assumes that any differences are ‘static’. Indeed, large sample sizes are required to identify reproducible baseline differences in functional connectivity between autistic and non-autistic individuals. Instead, we propose what is different in autism is not necessarily the baseline functional connectivity of resting-state networks, but rather their responsivity or regulation by neurotransmitter systems. We tested this hypothesis using a uniform analytical framework to capture the modulation of functional connectivity by single doses of pharmacological probes targeting three major neurotransmitter systems implicated in autism, namely gamma-amino-butyric-acid (GABA), serotonin (5HT) and mu opioid systems. Every drug challenge altered resting-state network connectivity differentially in the autistic compared to the non-autistic group. However, regardless of the neurotransmitter system probed, drug challenge elicited increases in between-network connectivity in autistic participants but minimal or decreased between-network connectivity in their non-autistic peers. There was no group difference in the responsivity of within-network connectivity. Thus, there is altered responsivity of neurotransmitter systems in the autistic brain. This has important implications for pharmacotherapy in autism because these neurotransmitter systems are the targets of several medications commonly prescribed to manage mental health conditions that frequently co-occur in autism. Investigating if these drug-induced ‘shifts’ in functional connectivity can help provide better targeted clinical interventions, will be important next translational steps.
One Sentence Summary Resting-state network connectivity is differentially modulated in autism by pharmacological probes targeting the GABAA, GABAB, serotonin and mu opioid neurotransmitter systems.
Competing Interest Statement
T.P.W. is an employee of Compass Pathfinder Ltd. and holds shares in the company. N.A.P. has consulted for Deerfield Discovery and Research. D.G.M.M. has consulted for Jaguar Gene Therapy LLC. G.M.M. has received funding for investigator-initiated studies from GW Pharmaceuticals and Compass Pathfinder Ltd.. G.M.M. has consulted for Greenwich Biosciences, Inc. L.G.S.F., M.D., C.M.P., H.V., A.C.P., C.L.E., G.I., J.L.F., R.H.W., F.M.P., J.K., N.M., N.M.L.W., D.B. and E.D. have no conflicts to declare.
Clinical Trial
NCT03678129, NCT03594552, NCT04145076
Funding Statement
The authors also receive support from EU-AIMS (European Autism Interventions)/EU AIMS-2-TRIALS, an Innovative Medicines Initiative Joint Undertaking under Grant Agreement No. 777394. In addition, this paper represents independent research part funded by the infrastructure of the National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre (BRC) at South London and Maudsley NHS Foundation Trust and Kings College London, and the Medical Research Council Centre for Neurodevelopmental Disorders. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was granted by the Kings College Research Ethics Committee (RESCM-17/18-4081), West Midlands - Solihull Research Ethics Committee (REC 18/WM/0208) and London - Stanmore Research Ethics Committee (REC 14/LO/0663).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* Joint senior authors
Data and Material Availability
Data from this study is available upon request.
